<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Colchicine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Colchicine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Colchicine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9293" href="/d/html/9293.html" rel="external">see "Colchicine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12339" href="/d/html/12339.html" rel="external">see "Colchicine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8108144"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Colcrys [DSC];</li>
<li>Gloperba;</li>
<li>Lodoco;</li>
<li>Mitigare</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866425"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>EURO-Colchicine;</li>
<li>JAMP-Colchicine;</li>
<li>Myinfla;</li>
<li>PMS-Colchicine;</li>
<li>SANDOZ Colchicine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046565"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Antigout Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F154325"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e33d38a2-a837-437c-9203-1a9273f46986">Familial Mediterranean Fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial Mediterranean Fever (FMF)</b>: Colcrys:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to 6 years: Oral: 0.3 to 1.8 mg/day in 1 to 2 divided doses; titrate by increasing or decreasing dose in 0.3 mg/day increments based on efficacy or adverse effects; maximum dose: 2.4 mg/<b>day</b>; some guidelines recommend a lower maximum daily dose (2 mg/<b>day</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26802180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26802180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;6 to 12 years: Oral: 0.9 to 1.8 mg/day in 1 to 2 divided doses; titrate by increasing or decreasing dose in 0.3 mg/day increments based on efficacy or adverse effects; maximum dose: 2.4 mg/<b>day</b>; some guidelines recommend a lower maximum daily dose (2 mg/<b>day</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26802180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26802180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;12 years and Adolescents: Oral: 1.2 to 2.4 mg/day in 1 to 2 divided doses; titrate by increasing or decreasing dose in 0.3 mg/day increments based on efficacy or adverse effects; maximum dose: 2.4 mg/<b>day</b>; some guidelines recommend a lower maximum daily dose (2 mg/<b>day</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26802180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26802180'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae31cac7-7452-46d7-b71b-8bdd5844202c">Gout</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout:</b> Colcrys: Adolescents &gt;16 years:</p>
<p style="text-indent:-2em;margin-left:4em;">Flare treatment: Initial: Oral: 1.2 mg at the first sign of flare, followed in 1 hour with a single dose of 0.6 mg (maximum dose: 1.8 mg over 1 hour). Patients receiving prophylaxis treatment may receive treatment dosing; wait 12 hours before resuming prophylactic dose; wait at least 3 days before repeating treatment dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis: Oral: 0.6 mg once or twice daily; maximum daily dose: 1.2 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090194"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Kidney impairment has been shown to be a significant risk factor for the development of colchicine-induced myotoxicity in adults, even with short-term use (eg, 4 to 7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3035372','lexi-content-ref-2023222','lexi-content-ref-15585444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3035372','lexi-content-ref-2023222','lexi-content-ref-15585444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Oral: Colcrys:</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Colchicine Dosage Adjustments in Altered Kidney </b>
<b>Function<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2"></th>
<th align="center">
<p style="text-indent:0em;">Familial Mediterranean fever</p></th>
<th align="center">
<p style="text-indent:0em;">Gout flare, treatment<sup>b,c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Gout flare, prophylaxis<sup>c</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Children ≥4 years and Adolescents</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Adolescents &gt;16 years</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Adolescents &gt;16 years</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Recommendations from manufacturer's labeling.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>In patients receiving prophylactic colchicine who have kidney impairment (CrCl &lt;80 mL/minute), treatment with colchicine for gout flares is not recommended.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup>Based on adult experience, many experts recommend avoiding colchicine for the treatment and prophylaxis of gout flares in severe kidney impairment (Bardin 2017; EULAR [Richette 2017]).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b> Mild to moderate impairment</b></p>
<p style="text-indent:0em;">
<b>(CrCl 30 to 80 mL/minute)</b></p></td>
<td align="center">
<p style="text-indent:0em;">There are no specific dosing recommendations in the manufacturer's labeling. Monitor closely for adverse effects; dose reduction may be necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary; monitor closely for adverse effects.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary; monitor closely for adverse effects.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Severe impairment</b></p>
<p style="text-indent:0em;">
<b>(CrCl &lt;30 mL/minute)<sup>c</sup></b></p></td>
<td align="center">
<p style="text-indent:0em;">Initial dose: 0.3 mg/day; use caution if titrating dose; monitor closely for adverse effects.</p></td>
<td align="center">
<p style="text-indent:0em;">Consider alternate therapy.</p>
<p style="text-indent:0em;">Treatment course should not be repeated more frequently than every 14 days. There are no specific dosage adjustments recommended by the manufacturer's labeling; however, based on adult recommendations, dosage adjustment may be necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">Consider alternate therapy. If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;margin-top:2em;">0.3 mg/day; titrate only if necessary and use extreme caution; monitor for adverse effects.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Hemodialysis, intermittent</b></p></td>
<td align="center">
<p style="text-indent:0em;">Nondialyzable: Initial dose: 0.3 mg/day; use caution if dose titrated; dosing can be increased with close monitoring for adverse effects.</p></td>
<td align="center">
<p style="text-indent:0em;">Nondialyzable; consider alternate therapy. If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;margin-top:2em;">0.6 mg as a single dose; wait at least 14 days to repeat.</p></td>
<td align="center">
<p style="text-indent:0em;">Nondialyzable; consider alternate therapy. If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;margin-top:2em;">0.3 mg twice <b>weekly</b>; monitor closely for adverse effects.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Peritoneal dialysis</b></p></td>
<td align="center">
<p style="text-indent:0em;">Nondialyzable: Initial dose: 0.3 mg/day; use caution if dose titrated; dosing can be increased with close monitoring for adverse effects.</p></td>
<td align="center">
<p style="text-indent:0em;">Nondialyzable; consider alternate therapy. If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;margin-top:2em;">0.6 mg as a single dose; wait at least 14 days to repeat.</p></td>
<td align="center">
<p style="text-indent:0em;">Nondialyzable; consider alternate therapy. If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;margin-top:2em;">0.3 mg twice <b>weekly</b>; monitor closely for adverse effects.</p></td></tr></tbody></table></div>
<div class="block dohp drugH1Div" id="F51261098"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Concurrent use of colchicine and P-gp or strong CYP3A4 inhibitors is <b>contraindicated</b> in hepatic impairment. Fatal toxicity has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>FMF:</i> Children ≥4 years and Adolescents: Colcrys: Oral</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Use caution; monitor closely for adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no specific dosage adjustments provided in the manufacturer's labeling; dosage adjustment should be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Gout prophylaxis:</i> Adolescents &gt;16 years: Colcrys: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No adjustment is necessary; however, monitor closely for adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no specific dosage adjustments provided in the manufacturer's labeling; dosage adjustment should be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Gout flare treatment:</i>
<b>Note:</b> Treatment of gout flares is not recommended in patients with hepatic impairment who are receiving colchicine for prophylaxis. Adolescents &gt;16 years: Colcrys: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No adjustment is necessary; however, monitor closely for adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: No adjustment is necessary; however, treatment course should not be repeated more frequently than every 14 days. Alternative therapy should be considered in patients requiring repeat courses.</p></div>
<div class="block doa drugH1Div" id="F154306"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9293" href="/d/html/9293.html" rel="external">see "Colchicine: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Colchicine has a narrow therapeutic index; drug accumulation can be associated with severe, including fatal, consequences. Monitor for signs/symptoms of colchicine toxicity and factors contributing to accumulation (eg, hepatic/renal impairment, drug interactions).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a46444ff-67a7-4fc5-abbb-ce290f52a5c7">Atherosclerotic cardiovascular disease, risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atherosclerotic cardiovascular disease, risk reduction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider for use in patients with stable atherosclerotic cardiovascular disease who are already receiving other therapies to reduce risk of cardiovascular events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32865380','lexi-content-ref-31733140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32865380','lexi-content-ref-31733140'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.5 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff6e1a22-9463-46c0-8867-6c9544232546">Behçet syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Behçet syndrome (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For treatment and/or prevention of recurrence in patients with arthritis, cutaneous lesions, and/or mucocutaneous ulcers.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 to 2 mg/day (or 1.2 to 1.8 mg/day) in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6778795','lexi-content-ref-23153327','lexi-content-ref-19597921','lexi-content-ref-29625968','lexi-content-ref-Smith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6778795','lexi-content-ref-23153327','lexi-content-ref-19597921','lexi-content-ref-29625968','lexi-content-ref-Smith.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c71adf7e-9cc7-4839-8526-0aafaf567d24">Calcium pyrophosphate crystal arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium pyrophosphate crystal arthritis ("pseudogout") (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to limited data, experts often approach treatment and prophylaxis of these patients the same as patients with gout (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenthal.1','lexi-content-ref-21257614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenthal.1','lexi-content-ref-21257614'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i> Patients with ≥3 calcium pyrophosphate crystal arthritis attacks annually: Limited data available: <b>Oral:</b> 0.6 mg twice daily (up to 1.2 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3772928','lexi-content-ref-Rosenthal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3772928','lexi-content-ref-Rosenthal.1'])">Ref</a></span>). In patients with GI intolerance, some experts give 0.6 mg once daily <b>or</b> 0.6 mg every other day; however, evidence for doses lower than 0.6 mg twice daily is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenthal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenthal.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment</i>
<b>:</b>
<b>Note: </b>Treatment should be initiated as soon as possible and within 36 hours of symptom onset; greatest response is seen when administered within 12 hours of symptom onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pascart.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pascart.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Day 1: <b>Oral:</b> 1.2 mg at the first sign of flare, followed in 1 hour with a single dose of 0.6 mg; do not exceed 1.8 mg/day on day 1 of flare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pascart.1','lexi-content-ref-Rosenthal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pascart.1','lexi-content-ref-Rosenthal.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Day 2 and thereafter: <b>Oral:</b> 0.6 mg twice daily until flare resolves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenthal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenthal.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd2834ea-9693-41ae-856f-f7f4864e097c">Familial Mediterranean fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial Mediterranean fever (FMF):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For prevention of attacks, and prevention of development and progression of amyloidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial: </i>
<b>Oral:</b> 1 to 1.5 mg/day (or 1.2 to 1.8 mg/day) in a single daily dose; if single daily doses are not tolerated, give in divided doses. May consider a lower initial dose of 0.5 mg (or 0.6 mg) with subsequent dose escalation to improve tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26802180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26802180'])">Ref</a></span>). <b>Note: </b>Consider a higher initial dose (eg, up to 2 mg/day) in patients with greater disease activity and renal amyloidosis (but preserved renal function); in patients with secondary (AA) amyloidosis, daily doses &gt;1.5 mg have been associated with prevention of disease progression and a reduction in protein excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1584316','lexi-content-ref-1736782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1584316','lexi-content-ref-1736782'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Titration:</i>
<b>Oral:</b> Increase the dose in 0.5 mg (or 0.6 mg) increments as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26802180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26802180'])">Ref</a></span>); upwards titration is recommended in patients with attacks more frequent than every 3 months and/or with persistently elevated inflammatory markers. In general, a 3-month period of steady colchicine dosing is advised before judging response, although a more rapid titration schedule may be considered based on frequency of attacks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23742958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23742958'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maximum:</i>
<b>Oral:</b> 3 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26802180','lexi-content-ref-23742958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26802180','lexi-content-ref-23742958'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6e76d75-22ca-4f0b-a2dd-704b9135d6b7">Gout, prophylaxis during initiation of urate-lowering therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, prophylaxis during initiation of urate-lowering therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.6 mg once or twice daily (maximum: 1.2 mg/day). In patients with GI intolerance, some experts give 0.6 mg every other day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Perez-Ruiz.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Perez-Ruiz.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients without tophi: 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934','lexi-content-ref-27457514','lexi-content-ref-Perez-Ruiz.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934','lexi-content-ref-27457514','lexi-content-ref-Perez-Ruiz.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with ≥1 tophi: Optimal duration is unclear; some experts continue colchicine therapy for 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Perez-Ruiz.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Perez-Ruiz.2023'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a81184b-235e-4be1-8cc9-23a33b10cc65">Gout, treatment, acute flares</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment, acute flares:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Day 1:</i>
<b> Oral: </b>1.2 mg at the first sign of flare, followed by 0.6 mg after 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27802508','lexi-content-ref-27457514','lexi-content-ref-20131255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27802508','lexi-content-ref-27457514','lexi-content-ref-20131255'])">Ref</a></span>); maximum total dose: 1.8 mg/day on day 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20131255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20131255'])">Ref</a></span>). Initiate as soon as possible, ideally within 12 to 24 hours of flare onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27457514','lexi-content-ref-20131255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27457514','lexi-content-ref-20131255'])">Ref</a></span>). <b>Note: </b>In patients who were already receiving prophylactic colchicine at the time of their flare, some experts give the higher 1.8 mg/day dosing regimen on day 1 of the flare, in place of the usual prophylactic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Day 2 and thereafter:</i>
<b>Oral:</b> 0.6 mg once or twice daily until flare resolves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27802508','lexi-content-ref-32391934','lexi-content-ref-27457514','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27802508','lexi-content-ref-32391934','lexi-content-ref-27457514','lexi-content-ref-Manu.1'])">Ref</a></span>). Some experts continue for 48 hours after flare resolves; if symptoms do not improve after 2 to 3 days, consider switching to other anti-inflammatory agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1'])">Ref</a></span>).<b> Note:</b> In patients who were already receiving prophylaxis at the time of their flare, some experts give 0.6 mg twice daily (total dose: 1.2 mg/day) from day 2 until ~48 hours after flare resolution, and then resume the previous prophylactic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Historically, higher dose regimens have been given for gout flares; however, high-dose regimens have not been proven more effective than low-dose regimens and low-dose regimens have a better safety profile (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27457514','lexi-content-ref-20131255','lexi-content-ref-25180124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27457514','lexi-content-ref-20131255','lexi-content-ref-25180124'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="236d546c-b735-4016-861b-18e58e48239e">Pericarditis, acute or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pericarditis, acute </b>
<b>or recurrent (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Loading dose:</i> Loading doses are not necessary; avoiding loading doses may improve adherence to therapy and reduce adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Adler.1','lexi-content-ref-26320112','lexi-content-ref-Imazio.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Adler.1','lexi-content-ref-26320112','lexi-content-ref-Imazio.1'])">Ref</a></span>). If a decision to use a loading dose is made, the following is recommended:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients ≥70 kg:</i>
<b>Oral:</b> 1 mg (or 1.2 mg) every 12 hours on day 1, followed by maintenance dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16186468','lexi-content-ref-21873705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16186468','lexi-content-ref-21873705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients &lt;70 kg or unable to tolerate higher dosing regimen: </i>
<b>Oral:</b> 0.5 mg (or 0.6 mg) every 12 hours on day 1, followed by maintenance dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16186468','lexi-content-ref-21873705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16186468','lexi-content-ref-21873705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients ≥70 kg:</i>
<b>Oral:</b> 0.5 mg (or 0.6 mg) twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16186468','lexi-content-ref-21873705','lexi-content-ref-23992557','lexi-content-ref-24694983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16186468','lexi-content-ref-21873705','lexi-content-ref-23992557','lexi-content-ref-24694983'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients &lt;70 kg or unable to tolerate higher dosing regimen:</i>
<b>Oral:</b> 0.5 mg (or 0.6 mg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16186468','lexi-content-ref-21873705','lexi-content-ref-23992557','lexi-content-ref-24694983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16186468','lexi-content-ref-21873705','lexi-content-ref-23992557','lexi-content-ref-24694983'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial treatment (first occurrence): 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23992557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23992557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Recurrence treatment (first recurrence or multiple recurrences): 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24694983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24694983'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Concomitant therapy:</i> Use in combination with aspirin or a nonsteroidal anti-inflammatory drug (NSAID); may also add a corticosteroid for refractory cases. Alternatively, colchicine may be used with a corticosteroid alone if aspirin or an NSAID is contraindicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26320112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26320112'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="942eeba5-1cf1-4147-9f75-45fbe7ca8363">Postpericardiotomy syndrome, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postpericardiotomy syndrome, prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Initiate preventive therapy preoperatively (48 to 72 hours prior to surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25172965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25172965'])">Ref</a></span>)) <b>or</b> postoperatively (24 to 72 hours after surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoit.2018','lexi-content-ref-20805112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoit.2018','lexi-content-ref-20805112'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients ≥70 kg: <b>Oral:</b> 0.5 mg (or 0.6 mg) twice daily for 1 month</p>
<p style="text-indent:-2em;margin-left:6em;">Patients &lt;70 kg: <b>Oral:</b> 0.5 mg (or 0.6 mg) once daily for 1 month</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a02e34d3-2cf6-4410-a15f-3227272f972d">Sweet syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sweet syndrome (acute febrile neutrophilic dermatosis) (alternative agent</b>
<b>) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Dosage range studied: 1 to 1.5 mg/day (1.2 to 1.8 mg/day) in 1 to 3 divided doses; the mean duration of therapy in one case series was reported as 15 days (range: 10 to 21 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10233302','lexi-content-ref-7295564','lexi-content-ref-6821647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10233302','lexi-content-ref-7295564','lexi-content-ref-6821647'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ba1a08f-effd-47fb-a2d1-9e2bea4b8c4e">Vasculitis, idiopathic cutaneous small-vessel</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasculitis, idiopathic cutaneous small-vessel (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in patients who do not respond adequately to initial therapy with corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fett.1','lexi-content-ref-24756249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fett.1','lexi-content-ref-24756249'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Usual dose studied: 0.6 mg twice daily (Callen 1985; Callen 1987); if no response after 1 to 2 weeks, may consider increasing to 0.6 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24756249','lexi-content-ref-22741934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24756249','lexi-content-ref-22741934'])">Ref</a></span>); continue therapy for 2 to 3 months after lesions heal and no new lesions develop, then taper and discontinue therapy over several weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fett.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fett.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991708"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Kidney impairment is a significant risk factor for the development of colchicine-induced myotoxicity, even with short-term use (eg, 4 to 7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3035372','lexi-content-ref-2023222','lexi-content-ref-15585444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3035372','lexi-content-ref-2023222','lexi-content-ref-15585444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral:</b></p>
<table border="1" data-table-id="cefepime" frame="border" rules="all">
<caption style="text-align:center;">
<b>Colchicine Dosage Adjustments in Altered Kidney Function<sup>a </sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)<sup>b</sup></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Atherosclerotic cardiovascular disease, risk reduction (Lodoco)</b></p></th>
<th align="center">
<p style="text-indent:0em;">Gout flare, treatment<sup>c,d</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Gout flare, prophylaxis<sup>d</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Familial Mediterranean fever</p></th>
<th align="center">
<p style="text-indent:0em;">Off-label indications</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="6" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Recommendations from manufacturer's labeling and expert opinion unless otherwise specified.</p></td></tr>
<tr>
<td align="left" colspan="6" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Calculated using the Cockcroft-Gault formula.</p></td></tr>
<tr>
<td align="left" colspan="6" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Use of colchicine to treat gout flares is not recommended in patients with kidney impairment (CrCl &lt;80 mL/minute) receiving prophylactic colchicine.</p></td></tr>
<tr>
<td align="left" colspan="6" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Many experts recommend avoiding colchicine for the treatment and prophylaxis of gout flares in severe kidney impairment (Bardin 2017; El-Zawawy 2010; EULAR [Richette 2017]; Gaffo 2023).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>30 to 80</b></p></td>
<td align="center">
<p style="text-indent:0em;">There are no specific dose adjustments provided in the manufacturer's labeling; however, total clearance of colchicine is significantly reduced with kidney impairment; monitor closely for adverse effects.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p>
<p style="text-indent:0em;">Alternatively, some experts limit the dose to 0.6 mg daily in patients with CrCl 30 to 60 mL/minute (Perez-Ruiz 2023).</p></td>
<td align="center">
<p style="text-indent:0em;">No specific dosage adjustments are recommended; however, use of a reduced dose should be considered.</p></td>
<td align="center">
<p style="text-indent:0em;">No specific dose adjustments recommended; consider risks/benefits of utilizing the usual indication-specific dose versus a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>&lt;30<sup>d</sup></b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>
<i>CrCl 15 to &lt;30 mL/minute</i></b>
<i>: </i>There are no specific dose adjustments provided in the manufacturer's labeling; however, total clearance of colchicine is significantly reduced with kidney impairment; monitor closely for adverse effects.</p>
<p style="text-indent:0em;">
<b>
<i>CrCl &lt;15 mL/minute:</i></b> Contraindicated.</p></td>
<td align="center">
<p style="text-indent:0em;">Consider alternate therapy (preferred). If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;">1.2 mg at the first sign of flare, followed in 1 hour with a single dose of 0.6 mg; repeat treatment should not occur for at least 14 days.</p>
<p style="text-indent:0em;">Alternatively, some experts recommend a single dose of 0.3 mg at the first sign of a flare; if flare symptoms persist after 3 days, may consider subsequent doses of no more than 0.3 mg every 3 days until flare resolves (Gaffo 2023).</p></td>
<td align="center">
<p style="text-indent:0em;">Consider alternate therapy (preferred). If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;">0.3 mg once daily (or 0.6 mg every other day); titrate only if necessary and with extreme caution.</p>
<p style="text-indent:0em;">Maximum: 0.6 mg/day (expert opinion).</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.3 mg once daily; titrate in 0.3 mg increments (refer to adult dosing for titration frequency). Risk of toxicity is high; monitor closely (Ozen 2016).</p>
<p style="text-indent:0em;">Maximum: 1.5 mg/day (expert opinion).</p></td>
<td align="center">
<p style="text-indent:0em;">No specific dose adjustments recommended; consider risks/benefits of utilizing the usual indication-specific dose versus a reduced dose.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Minimally dialyzed (≤10%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8670333','lexi-content-ref-25385362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8670333','lexi-content-ref-25385362'])">Ref</a></span>):<b> Oral:</b></p>
<table border="1" data-table-id="cefepime" frame="border" rules="all">
<caption style="text-align:center;">
<b>Colchicine Dosage Adjustment in Hemodialysis (Intermittent [Thrice Weekly])<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Atherosclerotic cardiovascular disease, risk reduction (Lodoco)</b></p></th>
<th align="center">
<p style="text-indent:2em;">Gout flare, treatment<sup>b,c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Gout flare, prophylaxis<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Familial Mediterranean fever</p></th>
<th align="center">
<p style="text-indent:0em;">Off-label indications</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Recommendations from manufacturer's labeling and expert opinion unless otherwise specified.</p></td></tr>
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Use of colchicine to treat gout flares is not recommended in patients with kidney impairment (CrCl &lt;80 mL/minute) receiving prophylactic colchicine.</p></td></tr>
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Many experts recommend avoiding colchicine for the treatment and prophylaxis of gout flares in severe kidney impairment (Bardin 2017; El-Zawawy 2010; EULAR [Richette 2017]; Gaffo 2023).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Contraindicated.</p></td>
<td align="center">
<p style="text-indent:0em;">Consider alternate therapy (preferred). If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;">A single dose of 0.6 mg at the first sign of flare; repeat treatment should not occur for at least 14 days.</p>
<p style="text-indent:0em;">Alternatively, some experts recommend a single dose of 0.3 mg at the first sign of flare; repeat treatment should not occur for at least 3 to 7 days (expert opinion).</p></td>
<td align="center">
<p style="text-indent:0em;">Consider alternate therapy (preferred). If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;">0.3 mg twice <b>weekly</b>.</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.3 mg once daily; titrate in 0.3 mg increments (refer to adult dosing for titration frequency). Risk of toxicity is high; monitor closely (Ozen 2016).</p>
<p style="text-indent:0em;">Maximum: 1.5 mg/day (Solak 2014; expert opinion).</p></td>
<td align="center">
<p style="text-indent:0em;">No specific dose adjustments recommended; consider risks/benefits of utilizing the usual indication-specific dose versus a reduced dose.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: Oral:</b></p>
<table border="1" data-table-id="cefepime" frame="border" rules="all">
<caption style="text-align:center;">
<b>Colchicine Dosage Adjustments in Peritoneal Dialysis<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Atherosclerotic cardiovascular disease, risk reduction (Lodoco)</p></th>
<th align="center">
<p style="text-indent:0em;">Gout flare, treatment<sup>b,c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Gout flare, prophylaxis<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Familial Mediterranean fever</p></th>
<th align="center">
<p style="text-indent:0em;">Off-label indications</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Recommendations from manufacturer's labeling and expert opinion unless otherwise specified.</p></td></tr>
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Use of colchicine to treat gout flares is not recommended in patients receiving prophylactic colchicine.</p></td></tr>
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Many experts recommend avoiding colchicine for the treatment and prophylaxis of gout flares in severe kidney impairment (Bardin 2017; El-Zawawy 2010; EULAR [Richette 2017]; Gaffo 2023).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Contraindicated.</p></td>
<td align="center">
<p style="text-indent:0em;">Consider alternate therapy (preferred). If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;">A single dose of 0.6 mg at the first sign of flare; repeat treatment should not occur for at least 14 days.</p>
<p style="text-indent:0em;">Alternatively, some experts recommend a single dose of 0.3 mg at the first sign of flare; repeat treatment should not occur for at least 3 to 7 days (expert opinion).</p></td>
<td align="center">
<p style="text-indent:0em;">Consider alternate therapy (preferred). If alternate therapy is not available/tolerated, the following adjustment is recommended:</p>
<p style="text-indent:0em;">0.3 mg twice <b>weekly</b>.</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.3 mg once daily; titrate in 0.3 mg increments (refer to adult dosing for titration frequency). Risk of toxicity is high; monitor closely (Ozen 2016).</p>
<p style="text-indent:0em;">Maximum: 1.5 mg/day (Solak 2014; expert opinion).</p></td>
<td align="center">
<p style="text-indent:0em;">No specific dose adjustments recommended; consider risks/benefits of utilizing the usual indication-specific dose versus a reduced dose.</p></td></tr></tbody></table></div>
<div class="block doha drugH1Div" id="F50989029"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Concurrent use of colchicine and P-gp or strong CYP3A4 inhibitors is <b>contraindicated</b> in hepatic impairment. Fatal toxicity has been reported. Treatment of gout flare with colchicine is not recommended in patients with hepatic impairment receiving prophylactic colchicine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Atherosclerotic cardiovascular disease, risk reduction (Lodoco):</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: There are no specific dose adjustments provided in the manufacturer's labeling; however, clearance may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment; monitor closely for adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Familial Mediterranean fever:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Use caution; monitor closely for adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There is no specific dosage adjustment provided in the manufacturer's labeling; dosage adjustment should be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Gout prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment:</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet (eg, Colcrys): Dosage adjustment not required; monitor closely for adverse effects.</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule (eg, Mitigare) and oral solution (eg, Gloperba): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There is no specific dosage adjustment provided in the manufacturer's labeling; dosage adjustment should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic impairment with concomitant renal impairment: Capsule (eg, Mitigare) and oral solution (eg, Gloperba): Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Gout flare treatment:</i>
<b>Note:</b> Treatment of gout flares is not recommended in patients with hepatic impairment who are receiving colchicine for prophylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Dosage adjustment not required; monitor closely for adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Dosage reduction not required but may be considered; treatment course should not be repeated more frequently than every 14 days.</p></div>
<div class="block arsc drugH1Div" id="F55024488"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal effects, including <b>nausea</b>, <b>vomiting</b>, and <b>diarrhea,</b> are the most common side effects associated with colchicine therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29272515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29272515'])">Ref</a></span>). Symptoms generally resolve quickly after dose reduction or treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32054504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32054504'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. May be due to binding to tubulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25554368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25554368'])">Ref</a></span>) or an increase in prostaglandins, intestinal secretion, and gastrointestinal motility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32054504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32054504'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; generally occurs within 24 hours of treatment initiation, dose adjustments, or drug interaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20586571','lexi-content-ref-25554368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20586571','lexi-content-ref-25554368'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29272515','lexi-content-ref-20131255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29272515','lexi-content-ref-20131255'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20586571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20586571'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29272515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29272515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of P-gp inhibitors or CYP3A4 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29272515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29272515'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F154270"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (23%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 1</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, nausea (Slobodnick 2018), vomiting (Slobodnick 2018)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Colchicine: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Colchicine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Colchicine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Gout flare</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">59</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (21%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Respiratory: Pharyngolaryngeal pain (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Neuromuscular disease (toxic)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Levy 1999; Medani 2016), maculopapular rash (Medani 2016), skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, abdominal pain, dysgeusia (Syed 2016), lactose intolerance</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azoospermia, oligospermia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia (Leung 2015; Todd 2012), bone marrow depression (Leung 2015; Todd 2012), granulocytopenia (Leung 2015), leukopenia (Leung 2015; Todd 2012), pancytopenia (Leung 2015; Levy 1999; Todd 2012), purpuric disease (Medani 2016), thrombocytopenia (Leung 2015; Todd 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Abbott 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, myasthenia (Altiparmak 2002; Todd 2012; Wilber 2004), neuropathy (Altiparmak 2002; Levy 1999; Medani 2016), numbness (Pirzada 2001), paresthesia (Pirzada 2001), peripheral neuritis (Medani 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy (Altiparmak 2002; Levy 1999; Medani 2016; Wilber 2004), myotonia (Wilber 2004), rhabdomyolysis (risk factors include renal dysfunction, inappropriate use/dose, potential drug interactions) (Medani 2016; Wilber 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p></div>
<div class="block coi drugH1Div" id="F154285"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Tablet (eg, Colcrys): Concomitant use of a P-glycoprotein (P-gp) inhibitor or strong CYP3A4 inhibitor in presence of renal or hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Gloperba, Mitigare: Concomitant use of drugs that inhibit both P-gp and CYP3A4 in presence of renal or hepatic impairment; patients with both renal and hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Lodoco: Hypersensitivity to colchicine or any component of the formulation; concomitant use of P-gp inhibitors or strong CYP3A4 inhibitors; patients with renal failure (CrCl &lt;15 mL/minute) and severe hepatic impairment; preexisting blood dyscrasias.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to colchicine; serious GI, hepatic, renal, and cardiac disease; existing blood dyscrasias.</p></div>
<div class="block war drugH1Div" id="F154267"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: Can cause myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia, which can be life-threatening or fatal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular toxicity: Can cause neuromuscular toxicity and rhabdomyolysis. If a patient develops signs of neuromuscular toxicity, discontinue therapy, investigate other causes, and treat appropriately.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Clearance is decreased in hepatic impairment; may increase risk of adverse effects/toxicity. Dosage adjustments may be considered depending on degree of impairment or indication and may be affected by the use of concurrent medication (CYP3A4 or P-gp inhibitors).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Clearance is decreased in renal impairment; may increase risk of adverse effects/toxicity. Dosage adjustments may be required depending on degree of impairment or indication and may be affected by the use of concurrent medication (CYP3A4 or P-gp inhibitors).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults; consider dosage adjustments.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fatal overdose: Accidental and intentional fatal overdoses have been reported. Dosage associated with fatal toxicity is variable (eg, wide dosage range).</p></div>
<div class="block foc drugH1Div" id="F154279"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mitigare: 0.6 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.6 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gloperba: 0.6 mg/5 mL (150 mL) [contains benzyl alcohol, fd&amp;c red #40 (allura red ac dye), propylene glycol; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colcrys: 0.6 mg [DSC] [scored; contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lodoco: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.6 mg</p></div>
<div class="block geq drugH1Div" id="F154263"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F154287"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Colchicine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg (per each): $6.68 - $7.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Mitigare Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg (per each): $7.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gloperba Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/5 mL (per mL): $3.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Colchicine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg (per each): $5.76 - $11.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lodoco Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $19.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866426"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.6 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myinfla: 0.5 mg [contains fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block admp drugH1Div" id="F52612451"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals and maintain adequate fluid intake.</p></div>
<div class="block adm drugH1Div" id="F154282"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with water and maintain adequate fluid intake. May be administered without regard to meals.</p></div>
<div class="block hazard drugH1Div" id="F49104450"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F154297"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); some products allow for excursions between 15°C to 30°C (59°F to 86°F), see product labeling for more information. Protect from light and moisture.</p></div>
<div class="block meg drugH1Div" id="F8097684"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Colcrys:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F022352s026lbl.pdf%23page%3D25&amp;token=XIckac6T%2BHcTFwaVtohIrvJphSoIpeKNNweCn3VDkRf%2FXWqknXZgSrNxzqb9qhI7i61w88XssEOouw3W4qrpxEvZmbsaIwLP8MqCBsu9KnQOeg5YSLjlUMSZQ%2B%2FX%2BVny&amp;TOPIC_ID=13179" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022352s026lbl.pdf#page=25</a></p>
<p style="text-indent:-2em;margin-left:4em;">Gloperba:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F210942s000lbl.pdf%23page%3D11&amp;token=BZfiBJfp2MVhd%2FY2qsR%2FjcYzilIUMeu6BHW2daI2197ehfLF4bfSDaRTpaT6gMV4bD9qw1OS0snZBiHfOoJtdfWhGCw3OVYJkn1kkdD6l2NFFn25HB5WKBClIy0eiDAZ&amp;TOPIC_ID=13179" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf#page=11</a></p>
<p style="text-indent:-2em;margin-left:4em;">Mitigare:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F89939%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPEuhQ30pIkOUzMCstcem2d5uLJxr3b7C0UVif1vjNK23rwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=13179" target="_blank">https://www.fda.gov/media/89939/download</a></p></div>
<div class="block usep drugH1Div" id="F53566232"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of familial Mediterranean fever (FMF) (Colcrys: FDA approved in ages ≥4 years and adults); prevention and treatment of acute gout flares (Colcrys: FDA approved in ages &gt;16 years and adults; Mitigare: FDA approved in adults); reduction of risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease (Lodoco: FDA approved in adults). <b>Note:</b> Approved ages and indications for generic products may vary; consult labeling for specific information.</p></div>
<div class="block mst drugH1Div" id="F154346"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Colchicine may be confused with Cortrosyn</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F154332"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F154272"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Colchicine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Colchicine may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Colchicine. Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Colchicine. Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of P-gp inhibitors, and hepatic/renal function. See interaction monograph for details<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: May enhance the adverse/toxic effect of Colchicine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: May enhance the myopathic (rhabdomyolysis) effect of Colchicine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Colchicine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Colchicine may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Colchicine may enhance the adverse/toxic effect of Hormonal Contraceptives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated during and for 2 weeks after itraconazole in patients with impaired renal or hepatic function. In those with normal renal and hepatic function, reduce colchicine dose as directed. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): Colchicine may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, colchicine may decrease absorption of cyanocobalamin (vitamin B12). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): Colchicine may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, colchicine may decrease absorption of cyanocobalamin (vitamin B12). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Colchicine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: Consider avoiding use of sotorasib and narrow therapeutic index/sensitive P-gp substrates. If combined use is unavoidable, monitor for increased toxicities of the substrate and consider a decrease in the substrate dosage.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): May increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Colchicine. Management: Colchicine should not be used with tipranavir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with tipranavir.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F154299"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may increase colchicine serum concentrations. Management: Administer orally with water and maintain adequate fluid intake. Avoid grapefruit juice.</p></div>
<div class="block dic drugH1Div" id="F154288"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May need to supplement with vitamin B<sub>12</sub>. Avoid grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F53110032"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Colchicine should not be discontinued in females with familial Mediterranean fever who are planning a pregnancy (EULAR [Ozen 2016]). Conception in females with rheumatic and musculoskeletal diseases should be planned during a period of quiescent/low disease activity (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Continuation of colchicine therapy is strongly recommended for use in males with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]). Use in males may rarely be associated with reversible infertility. A temporary dose reduction or discontinuation may be needed if azoospermia or oligospermia is related to use; however, men generally do not need to discontinue colchicine prior to conception (EULAR [Ozen 2016]).</p></div>
<div class="block pri drugH1Div" id="F10923644"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Colchicine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, an increased risk of major birth defects or pregnancy loss has not been observed following maternal use of colchicine for the treatment of rheumatic diseases, such as familial Mediterranean fever (FMF) (EULAR [Ozen 2016]; Indraratna 2018). However, untreated FMF is associated with adverse pregnancy outcomes including abortion, miscarriage, and exacerbations of FMF attacks (EULAR [Ozen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Colchicine can be continued during pregnancy in females with rheumatic and musculoskeletal diseases (ACR [Sammaritano 2020]). Available guidelines recommend continuing colchicine during pregnancy for the treatment of conditions such as FMF when there are no acceptable alternatives and discontinuation of treatment may lead to uncontrolled disease and adverse pregnancy outcomes. Increased monitoring during pregnancy is recommended; amniocentesis is not warranted (ACR [Sammaritano 2020]; EULAR [Ozen 2016]).</p></div>
<div class="block mopp drugH1Div" id="F53566227"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, urinalysis, and renal and hepatic function tests</p>
<p style="text-indent:-2em;margin-left:2em;">FMF: CRP, serum amyloid A (SAA) protein (every 3 months during dose escalation), creatinine phosphokinase (CPK), proteinuria, GFR (EULAR [Ozen 2016])</p></div>
<div class="block pha drugH1Div" id="F154266"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Disrupts cytoskeletal functions by inhibiting β-tubulin polymerization into microtubules, preventing activation, degranulation, and migration of neutrophils associated with mediating some gout symptoms. In familial Mediterranean fever, may interfere with intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediate activation of interleukin-1β.</p></div>
<div class="block phk drugH1Div" id="F154284"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: Pain relief: ~18 to 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Concentrates in leukocytes, kidney, spleen, and liver; does not distribute in heart, skeletal muscle, and brain</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: 5 to 8 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~39%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 and glucuronidation; 3 metabolites (2 primary, 1 minor)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~45%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 27 to 31 hours (multiple oral doses; young, healthy volunteers)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 0.5 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (40% to 65% as unchanged drug); enterohepatic recirculation, biliary excretion, and p-glycoprotein efflux also possible</p></div>
<div class="block phksp drugH1Div" id="F51220856"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Patients with ESRD had 75% lower clearance and prolonged elimination half-life.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance is significantly reduced and plasma half-life prolonged in patients with mild to moderate cirrhosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Mean peak plasma levels and AUC were 2 times higher in elderly patients; however, this may be caused by decreased renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F154289"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Colchicina houde | Colchicina phoenix | Colchicine houde | Xuric</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Colchicin tiofarma | Colchicina | Colctab</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Colcine | Colgout | Lengout</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Colimax | Kolchin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Colchicine houde</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Colchicine opocalcium</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Colchicin | Colchicine ecopharm | Colchicum dispert | Licocin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cixin | Cocichimil | Colchicina | Colchin | Colchis | Colcitrat | Colzuric | Coxym | Goltrite | Reugot</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Colchicin Streuli | Colchicine houde | Colctab</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Colchicina</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Colchicina | Colchimedio</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Colchicum dispert</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Colchicin tiofarma | Colchicin ysat</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Colchicina | Colchimedio</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Artrichine | Colchimedio</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Colchicin tiofarma | Colchicin ysat | Colchicina seid | Colchicine mylan | Colchicum dispert</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Colmediten</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Colchicine houde</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Colchicin | Colrefuz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Colchicine Opocalium</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Colchicine kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Colchicina Lirca | Colchicina/med line | Colchicine seid | Colchicine/farmasyn</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Colchily | Colcina | Colgout | Cp-Colchi | Kolcine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Colchicum dispert</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ar gout | Colcitine | Frigout | Kolchisina | Pyricin | Recolfar</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Colchicindon | Coljoy | Goutnil | Zycolchin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Colchicina Lirca</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Colmediten</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Colchicine alfresa | Colchicine hachi | Colchicine mitsubishi | Colchicine nakano | Colchicine s.s. seiyaku | Colchicine sawai | Colchicine shionogi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Goutnil | Kolzine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Colchin | Colchine | Colchinine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Colmediten</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Colchicine benta | Colchicine seid | Colmediten</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Colchicin | Colchicina Lirca | Colchicum dispert</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Colchicine opocalcium</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Colchicin | Colchicin ysat | Colchicina | Colchicina Lirca | Colchicina seid | Colchicine mylan | Colchicine opocalcium | Colchicum dispert</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Colchicine houde</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Colchicina | Colchicina gi | Colchiquim | Sixol | Ticolcin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Colchimil | Goutnil | Goutnor | Tolchicine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Colchicine A | Colchicine Actavis | Colchicine mylan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Colchicine abbott | Colchicine Actavis | Colchicine opocalcium | Colchicine ria | Colchicine rph | Colchicine tiofarma | Colchicum dispert | Colrefuz | Kolkicin tiofarma | Kolkisin aurora medical | Kolkisin naf</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Colgout</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Articol | Colchicina | Colchisol | Gotecina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Beragout | Cocilone | Goutless | Goutnil | Goutrelief | Goutsaph | Lesirheu | Rhea colchicine | Vonwelt colchicine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Colchican | Colchicin | Colchicine genoptim | Colchicum dispert</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Colchicina millet | Colchicina quimfa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Colmediten</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Colchicina</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Colchicin | Colchicum dispert</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Colmediten | Pms colchicine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Colchimex | Colrefuz | Kolkicin | Kolkicin ebb | Kolkicin Medartuum | Kolkicin tiofarma</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Colcitex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Colchican | Colchicina seid | Colchicum dispert</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Chicine | Colchily | Colchimex | Colcine | Colcitex | Colmed | Colstarcine | Gocine | Goticine | Goutichine | Koji | M colchicine | Pipchicine | Prochic | Remecine | Tolchicine | Zoric</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Colchicina Lirca | Colchicine houde | Colchicine opocalcium</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Colchicum dispert | Kolsin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cocine | Cofoncin | Colcin | Colcine | Colicine | Conicine | Suyuni</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Colchicin | Colchicina Lirca | Colgout</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Colchicina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Dochicin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Choldix | Cinited | Cinwol | Colchicine houde | Colcine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29201931">
<a name="29201931"></a>Abbott CE, Xu R, Sigal SH. Colchicine-induced hepatotoxicity. <i>ACG Case Rep J</i>. 2017;4:e120. doi: 10.14309/crj.2017.120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/29201931/pubmed" id="29201931" target="_blank">29201931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320112">
<a name="26320112"></a>Adler Y, Charron P, Imazio M, et al; European Society of Cardiology (ESC). 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J</i>. 2015;36(42):2921-2964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/26320112/pubmed" id="26320112" target="_blank">26320112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adler.1">
<a name="Adler.1"></a>Adler Y. Recurrent pericarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6778795">
<a name="6778795"></a>Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet's disease. <i>Haematologica</i>. 1980;65(3):399-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/6778795/pubmed" id="6778795" target="_blank">6778795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25164988">
<a name="25164988"></a>Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A. Colchicine for pericarditis. <i>Cochrane Database Syst Rev</i>. 2014;(8):CD010652. doi:10.1002/14651858.CD010652.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/25164988/pubmed" id="25164988" target="_blank">25164988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12371628">
<a name="12371628"></a>Altiparmak MR, Pamuk ON, Pamuk GE, Hamuryudan V, Ataman R, Serdengecti K. Colchicine neuromyopathy: a report of six cases. <i>Clin Exp Rheumatol</i>. 2002;20(4 Suppl 26):S13-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/12371628/pubmed" id="12371628" target="_blank">12371628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3772928">
<a name="3772928"></a>Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. <i>J Rheumatol.</i> 1986;13(4):804-805.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/3772928/pubmed" id="3772928" target="_blank">3772928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669352">
<a name="28669352"></a>Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. <i>BMC Med</i>. 2017;15(1):123. doi:10.1186/s12916-017-0890-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/28669352/pubmed" id="28669352" target="_blank">28669352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9550491">
<a name="9550491"></a>Ben-Chetrit E, Backenroth R, Levy M. Colchicine clearance by high-flux polysulfone dialyzers. <i>Arthritis Rheum.</i> 1998;41(4):749-750. doi:10.1002/1529-0131(199804)41:4&lt;749::AID-ART29&gt;3.0.CO;2-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/9550491/pubmed" id="9550491" target="_blank">9550491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8670333">
<a name="8670333"></a>Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. <i>Arthritis Rheum</i>. 1996;39(7):1213-1217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/8670333/pubmed" id="8670333" target="_blank">8670333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4044947">
<a name="4044947"></a>Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. <i>J Am Acad Dermatol</i>. 1985;13(2, pt 1):193-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/4044947/pubmed" id="4044947" target="_blank">4044947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3603105">
<a name="3603105"></a>Callen JP, af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. <i>South Med J</i>. 1987;80(7):848-851.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/3603105/pubmed" id="3603105" target="_blank">3603105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colchicine.1">
<a name="Colchicine.1"></a>Colchicine tablet [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals (USA) Inc; October 2022.</div>
</li>
<li>
<div class="reference">
                  Colcrys (colchicine) [prescribing information]. Deerfield, IL: Takeda; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23153327">
<a name="23153327"></a>Dalvi SR, Yildirim R, Yazici Y. Behcet's syndrome. <i>Drugs.</i> 2012;72(17):2223-2241. doi: 10.2165/11641370-000000000-00000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/23153327/pubmed" id="23153327" target="_blank">23153327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11950246">
<a name="11950246"></a>Das SK, Mishra K, Ramakrishnan S, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. <i>Osteoarthritis Cartilage.</i> 2002;10(4):247-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/11950246/pubmed" id="11950246" target="_blank">11950246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19597921">
<a name="19597921"></a>Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. <i>Mod Rheumatol</i>. 2009;19(5):542-549. doi: 10.1007/s10165-009-0200-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/19597921/pubmed" id="19597921" target="_blank">19597921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21147946">
<a name="21147946"></a>El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? <i>Cleve Clin J Med</i>. 2010;77(12):919-928. doi:10.3949/ccjm.77a.09080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/21147946/pubmed" id="21147946" target="_blank">21147946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fett.1">
<a name="Fett.1"></a>Fett N. Management of adults with idiopathic cutaneous small vessel vasculitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed April 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20586571">
<a name="20586571"></a>Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. <i>Clin Toxicol (Phila)</i>. 2010;48(5):407-414. doi: 10.3109/15563650.2010.495348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/20586571/pubmed" id="20586571" target="_blank">20586571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391934">
<a name="32391934"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: 10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaffo.1">
<a name="Gaffo.1"></a>Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gloperba.1">
<a name="Gloperba.1"></a>Gloperba (colchicine) [prescribing information]. Palo Alto, CA: Scilex Holding Company; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24756249">
<a name="24756249"></a>Goeser MR, Laniosz V, Wetter DA. A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis. <i>Am J Clin Dermatol</i>. 2014;15(4):299-306. doi: 10.1007/s40257-014-0076-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/24756249/pubmed" id="24756249" target="_blank">24756249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26888948">
<a name="26888948"></a>Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Ann Rheum Dis</i>. 2016;75(5):795-810. doi: 10.1136/annrheumdis-2015-208840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/26888948/pubmed" id="26888948" target="_blank">26888948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7556843">
<a name="7556843"></a>Guillonneau M, Aigrain EJ, Galliot M, Binet MH, Darbois Y. Colchicine is excreted at high concentrations in human breast milk. <i>Eur J Obstet Gynecol Reprod Biol</i>. 1995;61(2):177-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/7556843/pubmed" id="7556843" target="_blank">7556843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29625968">
<a name="29625968"></a>Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Ann Rheum Dis.</i> 2018;77(6):808-818. doi:10.1136/annrheumdis-2018-213225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/29625968/pubmed" id="29625968" target="_blank">29625968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23742958">
<a name="23742958"></a>Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. <i>Semin Arthritis Rheum.</i> 2013;43(3):387-391. doi: 10.1016/j.semarthrit.2013.04.011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/23742958/pubmed" id="23742958" target="_blank">23742958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hoit.2018">
<a name="Hoit.2018"></a>Hoit B. Post-cardiac injury syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imazio.1">
<a name="Imazio.1"></a>Imazio M. Acute pericarditis: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24694983">
<a name="24694983"></a>Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. <i>Lancet.</i> 2014a;383(9936):2232-2237. doi:10.1016/S0140-6736(13)62709-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/24694983/pubmed" id="24694983" target="_blank">24694983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16186468">
<a name="16186468"></a>Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. <i>Arch Intern Med</i>. 2005a;165(17):1987-1991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/16186468/pubmed" id="16186468" target="_blank">16186468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16186437">
<a name="16186437"></a>Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. <i>Circulation</i>. 2005b;112(13):2012-2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/16186437/pubmed" id="16186437" target="_blank">16186437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873705">
<a name="21873705"></a>Imazio M, Brucato A, Cemin R, et al; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial.<i> Ann Intern Med.</i> 2011;155(7):409-414. doi:10.7326/0003-4819-155-7-201110040-00359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/21873705/pubmed" id="21873705" target="_blank">21873705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23992557">
<a name="23992557"></a>Imazio M, Brucato A, Cemin R, et al; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. <i>N Engl J Med.</i> 2013;369(16):1522-1528. doi:10.1056/NEJMoa1208536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/23992557/pubmed" id="23992557" target="_blank">23992557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25172965">
<a name="25172965"></a>Imazio M, Brucato A, Ferrazzi P, et al; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. <i>JAMA. </i>2014b;312(10):1016-1023. doi: 10.1001/jama.2014.11026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/25172965/pubmed" id="25172965" target="_blank">25172965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22442198">
<a name="22442198"></a>Imazio M, Brucato A, Forno D, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. <i>Heart</i>. 2012;98(14):1078-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/22442198/pubmed" id="22442198" target="_blank">22442198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20805112">
<a name="20805112"></a>Imazio M, Trinchero R, Brucato A, et al; COPPS Investigators. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. <i>Eur Heart J</i>. 2010;31(22):2749-2754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/20805112/pubmed" id="20805112" target="_blank">20805112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29029311">
<a name="29029311"></a>Indraratna PL, Virk S, Gurram D, Day RO. Use of colchicine in pregnancy: a systematic review and meta-analysis. <i>Rheumatology (Oxford).</i> 2018;57(2):382-387. doi:10.1093/rheumatology/kex353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/29029311/pubmed" id="29029311" target="_blank">29029311</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jamp-Colchicine (colchicine) [prescribing information]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; January 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024029">
<a name="23024029"></a>Khanna D, Khanna PP, Fitzgerald JD, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(10):1447-1461. doi:10.1002/acr.21773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/23024029/pubmed" id="23024029" target="_blank">23024029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22741934">
<a name="22741934"></a>Kinney MA, Jorizzo JL. Small-vessel vasculitis. <i>Dermatol Ther</i>. 2012;25(2):148-157. doi: 10.1111/j.1529-8019.2012.01535.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/22741934/pubmed" id="22741934" target="_blank">22741934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3035372">
<a name="3035372"></a>Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy.<i> N Engl J Med.</i> 1987;316(25):1562-1568. doi:10.1056/NEJM198706183162502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/3035372/pubmed" id="3035372" target="_blank">3035372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26228647">
<a name="26228647"></a>Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses. <i>Semin Arthritis Rheum</i>. 2015;45(3):341-350. doi: 10.1016/j.semarthrit.2015.06.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/26228647/pubmed" id="26228647" target="_blank">26228647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1862011">
<a name="1862011"></a>Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. <i>Pharmacotherapy</i>. 1991;11(3):196-211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/1862011/pubmed" id="1862011" target="_blank">1862011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1584316">
<a name="1584316"></a>Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. <i>Nephron</i>. 1992;60(4):418-422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/1584316/pubmed" id="1584316" target="_blank">1584316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lodoco.1">
<a name="Lodoco.1"></a>Lodoco (colchicine) [prescribing information]. Parsippany, NJ: AGEPHA Pharma USA LLC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10233302">
<a name="10233302"></a>Maillard H, Leclech C, Peria P, Avenel-Audran M, Verret JL. Colchicine for Sweet's syndrome. A study of 20 cases. <i>Br J Dermatol.</i> 1999;140(3):565-566.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/10233302/pubmed" id="10233302" target="_blank">10233302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2112191">
<a name="2112191"></a>Majeed HA, Carroll JE, Khuffash FA, et al, “Long-term Colchicine Prophylaxis in Children With Familial Mediterranean Fever (Recurrent Hereditary Polyserositis),” <i>J Pediatr</i>, 1990, 116(6):997-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/2112191/pubmed" id="2112191" target="_blank">2112191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10616706">
<a name="10616706"></a>Majeed HA, Rawashdeh M, el-Shanti H, Qubain H, Khuri-Bulos N, Shahin HM. Familial Mediterranean fever in children: the expanded clinical profile. <i>QJM</i>. 1999;92(6):309-318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/10616706/pubmed" id="10616706" target="_blank">10616706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2566048">
<a name="2566048"></a>Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. <i>Lancet</i>. 1989;1(8647):1093-1096. doi:10.1016/s0140-6736(89)92381-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/2566048/pubmed" id="2566048" target="_blank">2566048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26249546">
<a name="26249546"></a>Medani S, Wall C. Colchicine toxicity in renal patients - are we paying attention? <i>Clin Nephrol.</i> 2016;86(2):100-105. doi:10.5414/CN108343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/26249546/pubmed" id="26249546" target="_blank">26249546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2066854">
<a name="2066854"></a>Milunsky JM. Breast-feeding during colchicine therapy for familial Mediterranean fever. <i>J Pediatr</i>. 1991;119(1, pt 1):164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/2066854/pubmed" id="2066854" target="_blank">2066854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mitigare.1">
<a name="Mitigare.1"></a>Mitigare (colchicine) [prescribing information]. Columbus, OH: Hikma Specialty USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21740149">
<a name="21740149"></a>Mullins M, Cannarozzi AA, Bailey TC, Ranganathan P. Unrecognized fatalities related to colchicine in hospitalized patients.<i> Clin Toxicol (Phila).</i> 2011;49(7):648-652. doi:10.3109/15563650.2011.589844<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/21740149/pubmed" id="21740149" target="_blank">21740149</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Myinfla (colchicine) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28298380">
<a name="28298380"></a>Nestor LA, Tobin AM. Oral Sweet's syndrome occurring in ulcerative colitis [published online March 15, 2017].<i> BMJ Case Rep.</i> doi: 10.1136/bcr-2016-218249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/28298380/pubmed" id="28298380" target="_blank">28298380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32865380">
<a name="32865380"></a>Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. <i>N Engl J Med</i>. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/32865380/pubmed" id="32865380" target="_blank">32865380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23299937">
<a name="23299937"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. <i>Catheter Cardiovasc Interv</i>. 2013;82(1):E1-E27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/23299937/pubmed" id="23299937" target="_blank">23299937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26802180">
<a name="26802180"></a>Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. <i>Ann Rheum Dis.</i> 2016;75(4):644-651. doi: 10.1136/annrheumdis-2015-208690.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/26802180/pubmed" id="26802180" target="_blank">26802180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pascart.1">
<a name="Pascart.1"></a>Pascart T, Robinet P, Ottaviani S, et al. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. <i>Lancet Rheumatol.</i> Published online August 8, 2023. doi:10.1016/S2665-9913(23)00165-0</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perez-Ruiz.2023">
<a name="Perez-Ruiz.2023"></a>Perez-Ruiz F. Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17039178">
<a name="17039178"></a>Pirzada NA, Medell M, Ali II. Colchicine induced neuromyopathy in a patient with normal renal function. <i>J Clin Rheumatol</i>. 2001;7(6):374-376. doi:10.1097/00124743-200112000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/17039178/pubmed" id="17039178" target="_blank">17039178</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  pms-Colchicine [prescribing information]. Montreal, Quebec, Canada: Pharmascience Inc; July 2016.</div>
</li>
<li>
<div class="reference">
                  pms-Colchicine [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27055417">
<a name="27055417"></a>Polat A, Acikel C, Sozeri B, et al; FMF Arthritis Vasculitis and Orphan Disease Research in Pediatric Rheumatology (FAVOR). Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever--a randomized controlled noninferiority trial. <i>Arthritis Res Ther.</i> 2016;18:85. doi: 10.1186/s13075-016-0980-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/27055417/pubmed" id="27055417" target="_blank">27055417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27802508">
<a name="27802508"></a>Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. <i>Ann Intern Med.</i> 2017;166(1):58-68. doi: 10.7326/M16-0570.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/27802508/pubmed" id="27802508" target="_blank">27802508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457514">
<a name="27457514"></a>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenthal.1">
<a name="Rosenthal.1"></a>Rosenthal AK. Treatment of calcium pyrophosphate crystal deposition (CPPD) disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 17, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.1">
<a name="Smith.1"></a>Smith EL. Treatment of Behçet syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/treatment-of-behcet-syndrome" target="_blank">https://www.uptodate.com</a>. Accessed April 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22874645">
<a name="22874645"></a>Solak Y, Atalay H, Biyik Z, et al. Colchicine toxicity in end-stage renal disease patients: a case-control study.<i> Am J Ther.</i> 2014;21(6):e189-e195. doi:10.1097/MJT.0b013e31825a364a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/22874645/pubmed" id="22874645" target="_blank">22874645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25554368">
<a name="25554368"></a>Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. <i>Am J Med</i>. 2015;128(5):461-470. doi: 10.1016/j.amjmed.2014.12.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/25554368/pubmed" id="25554368" target="_blank">25554368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272515">
<a name="29272515"></a>Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. <i>Rheumatology (Oxford)</i>. 2018;57(suppl 1):i4-i11. doi: 10.1093/rheumatology/kex453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/29272515/pubmed" id="29272515" target="_blank">29272515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32054504">
<a name="32054504"></a>Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. <i>Arthritis Res Ther</i>. 2020;22(1):28. doi: 10.1186/s13075-020-2120-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/32054504/pubmed" id="32054504" target="_blank">32054504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7295564">
<a name="7295564"></a>Suehisa S, Tagami H. Treatment of acute febrile neutrophilic dermatosis (Sweet's syndrome) with colchicine. <i>Br J Dermatol.</i> 1981;105(4):483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/7295564/pubmed" id="7295564" target="_blank">7295564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6821647">
<a name="6821647"></a>Suehisa S, Tagami H, Inoue F, Matsumoto K, Yoshikuni K. Colchicine in the treatment of acute febrile neutrophilic dermatosis (Sweet's syndrome). <i>Br J Dermatol.</i> 1983;108(1):99-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/6821647/pubmed" id="6821647" target="_blank">6821647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26899755">
<a name="26899755"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.e1-e6. doi: 10.1016/j.amjmed.2016.02.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/26899755/pubmed" id="26899755" target="_blank">26899755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31733140">
<a name="31733140"></a>Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. <i>N Engl J Med</i>. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/31733140/pubmed" id="31733140" target="_blank">31733140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14573737">
<a name="14573737"></a>Terkeltaub RA. Clinical practice. Gout. <i>N Engl J Med</i>. 2003;349(17):1647-1655.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/14573737/pubmed" id="14573737" target="_blank">14573737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20131255">
<a name="20131255"></a>Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. <i>Arthritis Rheum</i>. 2010;62(4):1060-1068. doi: 10.1002/art.27327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/20131255/pubmed" id="20131255" target="_blank">20131255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23019065">
<a name="23019065"></a>Todd BA, Billups SJ, Delate T, et al. Assessment of the association between colchicine therapy and serious adverse events. <i>Pharmacotherapy</i>. 2012;32(11):974-980. doi: 10.1002/phar.1125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/23019065/pubmed" id="23019065" target="_blank">23019065</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2023222">
<a name="2023222"></a>Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout.<i> J Rheumatol.</i> 1991;18(2):264-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/2023222/pubmed" id="2023222" target="_blank">2023222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25385362">
<a name="25385362"></a>Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. <i>Clin Drug Investig.</i> 2014;34(12):845-855. doi:10.1007/s40261-014-0238-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/25385362/pubmed" id="25385362" target="_blank">25385362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25180124">
<a name="25180124"></a>Wechalekar MD, Vinik O, Moi JH, et al. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. <i>J Rheumatol Suppl.</i> 2014;92:15-25. doi: 10.3899/jrheum.140458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/25180124/pubmed" id="25180124" target="_blank">25180124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15585444">
<a name="15585444"></a>Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. <i>Pharmacotherapy</i>. 2004;24(12):1784-1792. doi:10.1592/phco.24.17.1784.52334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/15585444/pubmed" id="15585444" target="_blank">15585444</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11710724">
<a name="11710724"></a>Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet's syndrome. <i>Arthritis Rheum</i>. 2001;44(11):2686-2692. doi:10.1002/1529-0131(200111)44:11&lt;2686::aid-art448&gt;3.0.co;2-h<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/11710724/pubmed" id="11710724" target="_blank">11710724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T. Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1736782">
<a name="1736782"></a>Zemer D, Livneh A, Langevitz P. Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. <i>Ann Intern Med</i>. 1992;116(5):426.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/1736782/pubmed" id="1736782" target="_blank">1736782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21257614">
<a name="21257614"></a>Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. <i>Ann Rheum Dis.</i> 2011;70(4):571-575. doi: 10.1136/ard.2010.139360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/21257614/pubmed" id="21257614" target="_blank">21257614</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13179 Version 472.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
